Amyris (NASDAQ:AMRS) Rating Lowered to Sell at Zacks Investment Research

Amyris (NASDAQ:AMRSGet Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Monday, reports.

According to Zacks, “Amyris INC is an integrated renewable products company applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. The Company is engaged in the development of farmesene- a molecule, which serves as the base chemical building block for a wide range of renewable products to replace existing products that are derived from petroleum, plant or animal sources and that may be of lower quality or higher price. Amyris INC is headquartered in Emeryville, CA. “

Separately, began coverage on Amyris in a research report on Thursday, March 31st. They issued a “sell” rating on the stock. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from, Amyris presently has a consensus rating of “Hold” and an average target price of $19.17.

Shares of AMRS stock traded down $0.15 on Monday, reaching $2.21. The company’s stock had a trading volume of 1,010,454 shares, compared to its average volume of 6,033,747. The company has a quick ratio of 2.09, a current ratio of 1.77 and a debt-to-equity ratio of 1.26. Amyris has a 12-month low of $1.47 and a 12-month high of $17.42. The company has a market capitalization of $702.72 million, a P/E ratio of -1.80 and a beta of 1.63. The stock’s 50 day simple moving average is $3.99 and its 200-day simple moving average is $5.31.

Amyris (NASDAQ:AMRSGet Rating) last issued its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.07). Amyris had a negative return on equity of 609.82% and a negative net margin of 39.08%. The business had revenue of $57.71 million during the quarter, compared to analysts’ expectations of $65.45 million. During the same quarter last year, the business posted ($1.08) EPS. The company’s quarterly revenue was down 67.4% on a year-over-year basis. Research analysts expect that Amyris will post -0.8 EPS for the current year.

Several large investors have recently made changes to their positions in AMRS. Morgan Stanley grew its stake in shares of Amyris by 17.2% in the second quarter. Morgan Stanley now owns 478,581 shares of the biotechnology company’s stock worth $7,834,000 after purchasing an additional 70,223 shares during the last quarter. Commonwealth Equity Services LLC bought a new stake in shares of Amyris in the third quarter worth about $141,000. Cambridge Investment Research Advisors Inc. purchased a new stake in Amyris in the third quarter worth about $208,000. Advisor Group Holdings Inc. lifted its holdings in Amyris by 27.2% in the third quarter. Advisor Group Holdings Inc. now owns 90,535 shares of the biotechnology company’s stock worth $1,243,000 after buying an additional 19,364 shares during the period. Finally, Swiss National Bank lifted its holdings in Amyris by 3.6% in the third quarter. Swiss National Bank now owns 354,200 shares of the biotechnology company’s stock worth $4,863,000 after buying an additional 12,200 shares during the period. 49.43% of the stock is currently owned by hedge funds and other institutional investors.

Amyris Company Profile (Get Rating)

Amyris, Inc, a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets.

Featured Stories

Get a free copy of the Zacks research report on Amyris (AMRS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with's FREE daily email newsletter.